STATEMENT OF NEED/TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and patient care, the program features discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Select appropriate adjuvant therapy for patients with HER2-positive breast cancer, based on tumor characteristics and the risk-benefit profiles of the treatments.
• Evaluate the potential clinical utility of newly emerging technologies to assess ER and HER2 status of breast tumors.
• Incorporate results from the Oncotype DX™ assay, along with other prognostic factors, into clinical decisions regarding adjuvant chemotherapy regimens for patients with node-negative and node-positive breast cancer.
• Assess the emerging data on novel chemotherapy and biologic agents, and determine if these treatments should be used for appropriate patients with metastatic breast cancer.
• Evaluate emerging breast cancer clinical trial data, and determine how the data should be applied to clinical practice.
• Counsel appropriately selected patients about the option of participating in ongoing clinical trials, based on an awareness of the latest research.

PURPOSE OF THIS ISSUE OF BREAST CANCER UPDATE

The purpose of this special edition of Breast Cancer Update is to support the learning objectives by offering the perspectives of Drs Carlson, Geyer, Gralow, Hudis, Mackey, Muss, Paik, Perez, Robert, Smith and Wolff on the integration of emerging clinical research data into the management of breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Educational Assessment located at www.BreastCancerUpdate.com/CME. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. BreastCancerUpdate.com/ThinkTank includes an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

---

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

 

.

Home · Search

EDITOR
Neil Love, MD

TOPICS

Treatment of Early Breast Cancer
- Select publications

Treatment of Metastatic Breast Cancer
- Select publications

Breast Cancer Update - Think Tank:

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office